Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis.
about
Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis.Differential activation of peritoneal cells by subcutaneous treatment of rats with cryptococcal antigensCentral nervous system cryptococcosis in solid organ transplant recipients: clinical relevance of abnormal neuroimaging findings.Insights into the mechanisms of protective immunity against Cryptococcus neoformans infection using a mouse model of pulmonary cryptococcosisImmunotherapy markedly increases the effectiveness of antimicrobial therapy for treatment of Burkholderia pseudomallei infectionEffects of the hematoregulatory peptide SK&F 107647 alone and in combination with amphotericin B against disseminated candidiasis in persistently neutropenic rabbits.Interdependency of interleukin-10 and interleukin-12 in regulation of T-cell differentiation and effector function of monocytes in response to stimulation with Cryptococcus neoformans.Immunoregulation by capsular components of Cryptococcus neoformans.Adjunctive immune therapy for fungal infections.Cytokine profiles at admission can be related to outcome in AIDS patients with cryptococcal meningitisType 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.Antifungal prophylaxis during neutropenia and immunodeficiencyInterleukin-12 regulation of host defenses against Coccidioides immitisInterleukin-12 modulates the protective immune response in SCID mice infected with Histoplasma capsulatum.Proinflammatory cytokines in the treatment of bacterial and fungal infections.Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain.Interleukin-12-induced adhesion molecule expression in murine liverRole of Interleukin-12 in Protection against Pulmonary Infection with Methicillin-Resistant Staphylococcus aureus.Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models.Interleukin 12 is effective treatment for an established systemic intracellular infection: experimental visceral leishmaniasis.Comparative efficacies of four amphotericin B formulations--Fungizone, amphotec (Amphocil), AmBisome, and Abelcet--against systemic murine aspergillosis.HIV and co-infections.Animal models: an important tool in mycology.Cytokine and inducible nitric oxide synthase mRNA expression during experimental murine cryptococcal meningoencephalitis.Immunocompromised hosts: immunopharmacology of modern antifungals.Mechanisms by Which Interleukin-12 Corrects Defective NK Cell Anticryptococcal Activity in HIV-Infected Patients.Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection.Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment.Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani.Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice.Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi.Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformansInterleukin-12 in infectious diseases.Role of interleukin 12 in experimental neonatal sepsis caused by group B streptococci.T helper cell dichotomy to Candida albicans: implications for pathology, therapy, and vaccine design.Trends in immunotherapy of fungal infections.Proinflammatory and immunoregulatory functions of interleukin-12.The debate over the effector function of eosinophils in helminth infection: new evidence from studies on the regulation of vaccine immunity by IL-12.Experimental systemic infection with Cryptococcus neoformans var. grubii and Cryptococcus gattii in normal and immunodeficient mice.IL-12 and IFN-gamma are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice.
P2860
Q28379472-C635BC0C-B36C-449B-9F6B-A409B4A53F51Q28573435-C22F5411-5B46-47D3-9E99-277C07C4D28BQ30438585-DD63EA28-B3F6-44C9-AF93-E7405706EC53Q33499671-249ED7A0-C189-4322-9E2A-E21A0D7CC125Q33826261-FBC70AE1-F51A-4374-94F0-707B0B06BF83Q33977593-04BB789A-A58B-4482-B31F-A82031B71343Q34009212-DE90353C-92C1-43FC-B467-7D897080D98CQ34155052-AC7B0E9F-3679-4DBF-880D-3EBBA4D20AADQ34350401-72A543FA-ED86-493A-A0AF-0352BC274C5EQ35208706-ECE068D3-341E-48C0-90D6-76C3816A0017Q35372676-E15777A5-5AF7-4351-B1D0-707153162124Q35374928-82C7E649-4338-4530-A5CE-3FBA698BD770Q35516782-65B939CA-2335-44A0-837E-8EAB4ABED566Q35544061-A60CB639-92F1-4B31-9316-C00E1F41473AQ35633724-48E0DA96-3755-4A6E-9C26-8C7165B41326Q35689384-7604F1C8-B718-44D3-8A15-519D6757307FQ35763756-435B82A5-06F2-4BE8-8EDD-5DA1EA2600F4Q36075866-EDCC95E7-118F-4978-891A-7A09D54D6090Q36192774-AB69DB6D-C8B0-4352-8797-EFBBA108717BQ36364304-DF3A0A7B-47EE-4C1A-A844-BD4411FD9635Q36489697-4429248D-CFF8-4E5E-95B9-5B500E757468Q36970184-8F041A38-F275-436C-9874-9D16BF30D2CCQ37008692-F89F6570-7DF8-4228-BF06-9002203B41CBQ37115803-F6929236-EF39-4307-A648-B6EBF0301773Q37186705-C98D9A95-28B6-4FC9-AAC6-538C4E877EDEQ37208363-73DF8FCC-68AC-4981-8619-59C6F686E787Q37624656-44E04AC0-401B-4BB7-8BD9-321F840ED1C2Q38154164-211862DA-9040-4038-8BB6-8B630102D725Q38994045-6E8022D8-4820-41DE-9ECA-51A2CBBE8131Q39476468-53C49557-628A-4EF9-8FA5-3507C8AB293DQ39559044-09805E44-1FCD-43E1-94BA-665F1FA2B027Q39573339-63BA060F-7CA7-48A7-903A-4B136E62E167Q39820841-E0225133-220D-423C-B872-E8FEA9BFCE11Q39830920-6AE2778A-6D2A-41EF-A4F1-DEA4E6FCAAC0Q40928708-E2A2BED9-097D-49EC-B9B5-74E0AC2F4423Q41377990-E21EDC71-2FDD-4FF3-BB6D-C6E757DF1C44Q41722212-84EEB5F4-7834-4CB6-BC03-904D97BF37C1Q44704086-C3F04C0B-704E-4BFF-A083-B00FED873C22Q46689726-9AEFB2B3-CE52-4B10-ACC5-8BF18DA982B1Q54151565-122836A1-446D-49F2-9539-553841EFF7D4
P2860
Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Cytokine treatment of central ...... n experimental cryptococcosis.
@en
type
label
Cytokine treatment of central ...... n experimental cryptococcosis.
@en
prefLabel
Cytokine treatment of central ...... n experimental cryptococcosis.
@en
P2093
P2860
P356
P1476
Cytokine treatment of central ...... n experimental cryptococcosis.
@en
P2093
P2860
P304
P356
10.1128/AAC.38.3.460
P407
P577
1994-03-01T00:00:00Z